Why the CLINUVEL Pharmaceuticals share price surged 13% higher today

The CLINUVEL Pharmaceuticals Limited (ASX:CUV) share price is up 13% today on the back of positive news…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In morning trade the CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price has pushed notably higher once again.

At the time of writing the pharmaceutical company's shares are up 13% to $21.70.

This gain means that CLINUVEL's shares are now up a remarkable 144% since this time last year.

Why is the CLINUVEL share price storming higher today?

Investors have been fighting to get hold of its shares this morning after the release of a positive announcement related to its SCENESSE product in the United States.

SCENESSE is a drug used for the prevention of phototoxicity and anaphylactoid reactions in adult patients with erythropoietic protoporphyria (EPP).

According to the release, the US Food and Drug Administration (FDA) Division of Dermatology and Dental Products has set a Prescription Drug User Fee Act (PDUFA) date of July 8 2019.

This essentially means that a Priority Review has been granted for SCENESSE on July 8, which could lead to the drug going on sale in the United States in the near future if it can satisfy its requirements.

The company's chief scientific officer, Dr Dennis Wright was pleased with the news.

He said: "Acceptance of this NDA is the result of patience and hard work from the CLINUVEL team and medical community, bringing us a significant step closer to making SCENESSE available for US EPP patients,"

He added: "We are pleased with the work of the FDA to date and, contrary to our own expectations, the agency has stated that it does not intend to hold an advisory committee meeting for further review of the product."

The company advised that it will now work towards a positive and landmark outcome for EPP patients on July 8.

Should you invest?

This is a very positive development for the company and I can't say I'm surprised to see its shares take off today.

The U.S. market represents a major market for SCENESSE and could generate significant revenue for the company.

But with its valuation now ~$1 billion, I think CLINUVEL's shares are fully valued and would suggest investors look elsewhere at the likes of CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Happy coal miner.
Share Gainers

Up 75% this week, why is this ASX All Ords stock rocketing again today?

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a bountiful session for investors this hump day.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »

Man pointing at a blue rising share price graph.
Share Gainers

Guess which ASX 300 stock just rocketed 43% on big news!

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

Three friends leaping in the air in joy with a dog on the ground.
Share Gainers

Can May's top 3 performing ASX 50 stocks repeat in June?

These three blue chip stocks led the pack in the month of May. Do brokers think they can back it…

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back to the races this Tuesday.

Read more »

A woman reaches her arms to the sky as a plane flies overhead at sunset.
Travel Shares

Why the Qantas share price soared 20% in May to new all-time highs

With another stellar month in May, Qantas shares are up more than 79% in a year.

Read more »